Brief: Enhertu® Followed Biologics License Application Accepted In The U.S. For Patients With Early-Stage Breast Cancer Prior To Surgery
01/10/2025 12:15
Oct 1 (Reuters) - Daiichi Sankyo Co Ltd 4568.T: ENHERTU® FOLLOWED BY THP SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION ACCEPTED IN THE U.S. FOR PATIENTS WITH HIGH-RISK HER2 POSITIVE EARLY-STAGE BREAST CANCER PRIOR TO SURGERY DAIICHI SANKYO CO LTD - FDA TARGET ACTION DATE FOR ENHERTU IS MAY 18, 2026 Source text: ID:nBw9gvVPCa Further company coverage: 4568.T ((Reuters.Briefs@thomsonreuters.com;))